CHA ÀÇ°úÇдëÇб³ Â÷º´¿ø professor

±³¼ö´Ô»çÁø
  • ÀüÈ«Àç
  • ¾Ï¼¾ÅÍÀå
  • ¼Ò ¼Ó: ºÐ´çÂ÷º´¿ø
  • Àü¹®ºÐ¾ß : °£¾Ï/Ãé´ãµµ¾Ï
  • Á÷ À§: ºÎ±³¼ö(¾Ï¼¾ÅÍÀå)
  • ¸Þ ÀÏ: ºñ°ø°³
  • Àü È­: 1577-4488
  • ÆÑ ½º:
  • ÁÖ ¼Ò: °æ±âµµ ¼º³²½Ã ºÐ´ç±¸ ¾ßžµ¿ 351¹øÁö
  • ȨÆäÀÌÁö:
  • ·Î±×ÀÎ

ÅǸ޴º

ÁÖ¿ä¹ßÇ¥³í¹®

µî·Ï

ÁÖ¿ä¹ßÇ¥³í¹®
¹øÈ£ ±¸ºÐ Á¦¸ñ ´Ù¿î·Îµå
55 ÇØ¿Ü Chon HJ*, Kim HR*, Shin E, Kim C, Heo SJ, Lee C, Park JK, Noh SH, Chung HC, Rha SY. The Clinicopathological Features and Prognostic Impact of ALK-positivity in Resected Gastric Cancer Patients. Annals of Surgical Oncology 2015 (IF 3.943), 22(12):3938-45  
54 ÇØ¿Ü Park JS, Jeung HC, Rha SY, Ahn JB, Kang BD, Chon HJ, Hong MH, Lim ST, Yang WI, Nam CM, Chung HC. M. Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane. Cancer Chemother Pharmacol 2014 (IF 2.808)  
53 ÇØ¿Ü Kim C, Chon HJ, Kang B, Kim K, Jeung HC, Chung HC, Noh SH, Rha SY. Prediction of metachronous multiple primary cancers following the curative resection of gastric cancer. BMC Cancer 2013 (IF 3.319), 13(1):394.  
52 ÇØ¿Ü Chon HJ, SY Rha, Park HS, Shin SJ, Kim HS, Roh JK, Noh SH, Chung HC, Jeung HCl. Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer. Cancer Chemotherapy and Pharmacology (IF 2.769) October 2011, Volume 68, Issue 4, pp 991-999,  
51 ÇØ¿Ü Hong MH, Koo HM, Choi J, Ahn JR, Chon HJ, Kim C, Lee ST. A case of nephrogenic systemic fibrosis after gadolinium-based contrast agent injection. Korean Journal of Medicine 2010, 78(1):127-131.  
50 ÇØ¿Ü Chon HJ, Rha SY, Im CK, Kim C, Hong MH, Kim HR, Ahn JR, Noh SH, Chung HC, Jeung HC. Docetaxel versus paclitaxel combined with 5-FU and leucovorin in advanced gastric cancer: combined analysis of two phase II trials. Cancer Research and Treatment 2009 (IF 2.975), 41(4):196-204.  
49 ÇØ¿Ü Kim C, Shin E, Hong S, Chon HJ, Kim HR, Ahn JR, Hong MH, Yang WI, Roh JK, Rha SY. Clinical value of ezrin expression in primary osteosarcoma. Cancer Research and Treatment 2009 (IF 2.975), 41(3):138-144.  
48 ÇØ¿Ü Ahn JR, Hong M, Kim C, Hong MH, Chon HJ, Kim HR, Jeung HC, Hyung WJ, Lee SS, Chung HC, Noh SH, Rha SY. Prognosis of pN3 stage gastric cancer. Cancer Research and Treatment 2009 (IF 2.975), 41(2):73-79.  
47 ÇØ¿Ü Hong MH, Kim HS, Kim C, Ahn JR, Chon HJ, Shin SJ, Ahn JB, Chung HC, Rha SY. Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea. Cancer Research and Treatment 2009 (IF 2.975), 41(2):67-72.  
46 ÇØ¿Ü Oral presentation on ¡°Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer¡± (Korean Association for Clinical Oncology Meeting, 2010)  
ÀÌÀüÆäÀÌÁö À̵¿ 1 2 3 4 5 6 7 8 ´ÙÀ½ÆäÀÌÁö À̵¿
Copyright ¨Ï chamc, All rights reserved.

ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à

  • °­³²Â÷º´¿ø
  • ºÐ´çÂ÷º´¿ø
  • ºÐ´çÂ÷¿©¼ºº´¿ø
  • ±¸¹ÌÂ÷º´¿ø
  • ¿©¼ºÀÇÇבּ¸¼Ò
  • Â÷¿ò

ÀüÈ­¹®ÀÇ

  • °­³²Â÷º´¿ø 02.3468.3000
  • ºÐ´çÂ÷º´¿ø 031.780.5000
  • Â÷¿ò 02.3015.5300
  • ±¸¹ÌÂ÷º´¿ø 054.450.9700
  • ´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
  • °­³²°ÇÁø¼¾ÅÍ 02.2191.3900
  • ºÐ´çÁ¾ÇÕ°Ç°­ÁõÁø¼¾ÅÍ 031.780.5940
  • ½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
  • ±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
  • ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729